Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2B RANDOMIZED , DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Intervention/treatment:
ABROCITINIB (PF-04965842)
Medical condition:
ATOPIC DERMATITIS
Protocol code:
B7451006
Control number:
193125
Status:
Closed
Approved:
April 08, 2016
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT02780167
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer, Inc.
Phone:
1-800-718-1021
Sponsor
PFIZER CANADA INC

Locations

British Columbia

University of British Columbia
Vancouver, British Columbia, V5Z 4E8

Manitoba

Wiseman Dermatology Research Inc.
Winnipeg, Manitoba, R3M 3Z4

Ontario

K. Papp Clinical Research
Waterloo, Ontario, N2J 1C4
Lynderm Research Inc.
Markham, Ontario, L3P 1X2
Research by ICLS
Oakville, Ontario, L6J 7W5
Skin Centre for Dermatology
Peterborough, Ontario, K9J 5K2
The Centre for Dermatology
Richmond Hill, Ontario, L4B IA5
Windsor Clinical Research Inc
Windsor, Ontario, N8W 5L7

Quebec

Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
Québec, Quebec, G1V 4X7
Diex Research Sherbrooke Inc.
Sherbrooke, Quebec, J1H 1Z1
Innovaderm Research Inc.
Montreal, Quebec, H2K 4L5

Results

See the results from the trial NCT02780167. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?